Profil bibliographique

Binkui Li

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

201Publications signalées

4180Citations signalées

2Affiliations récentes

Les institutions déclarées

Sun Yat-sen University Sun Yat-sen University Cancer Center

Les domaines associés

Hepatocellular Carcinoma Treatment and PrognosisCancer Mechanisms and TherapyMicroRNA in disease regulationCholangiocarcinoma and Gallbladder Cancer StudiesCircular RNAs in diseases

Les publications récentes

Accès ouvert 2026 other OpenAlex

Data from HSPA6 Confers Lenvatinib Resistance in Hepatocellular Carcinoma by Promoting Phase Separation–Mediated TXNRD1 Stabilization to Suppress Ferroptosis

Yi Zeng, Zhenkun Huang, Jiliang Qiu, Guifang Yuan et autres

Abstract The development of therapy resistance compromises the long-term efficacy of lenvatinib in advanced hepatocellular carcinoma (HCC), highlighting the need to characterize the molecular drivers of resistance. Through integrated multiomics analysis combining genome-wide CRISPR screening, transcriptomics, and proteomics, we identified Heat shock …

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Fig. 5 from HSPA6 Confers Lenvatinib Resistance in Hepatocellular Carcinoma by Promoting Phase Separation–Mediated TXNRD1 Stabilization to Suppress Ferroptosis

Yi Zeng, Zhenkun Huang, Jiliang Qiu, Guifang Yuan et autres

HSPA6 recruits USP9X to stabilize TXNRD1

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Fig. 6 from HSPA6 Confers Lenvatinib Resistance in Hepatocellular Carcinoma by Promoting Phase Separation–Mediated TXNRD1 Stabilization to Suppress Ferroptosis

Yi Zeng, Zhenkun Huang, Jiliang Qiu, Guifang Yuan et autres

Lenvatinib-potentiated HSPA6 phase separation promotes TXNRD1-USP9X co-condensation and TXNRD1 stabilization

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Table 5 from HSPA6 Confers Lenvatinib Resistance in Hepatocellular Carcinoma by Promoting Phase Separation–Mediated TXNRD1 Stabilization to Suppress Ferroptosis

Yi Zeng, Zhenkun Huang, Jiliang Qiu, Guifang Yuan et autres

List of 1,047 upregulated genes identified by transcriptomic profiling of Huh7-LR cells compared with parental controls. (log2FoldChange > 1, pvalue < 0.05)

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Table 9 from HSPA6 Confers Lenvatinib Resistance in Hepatocellular Carcinoma by Promoting Phase Separation–Mediated TXNRD1 Stabilization to Suppress Ferroptosis

Yi Zeng, Zhenkun Huang, Jiliang Qiu, Guifang Yuan et autres

DepMap common essential genes used for filtering CRISPR/Cas9 screening candidates

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Fig. 4 from HSPA6 Confers Lenvatinib Resistance in Hepatocellular Carcinoma by Promoting Phase Separation–Mediated TXNRD1 Stabilization to Suppress Ferroptosis

Yi Zeng, Zhenkun Huang, Jiliang Qiu, Guifang Yuan et autres

HSPA6 upregulates TXNRD1 to suppress ferroptosis and promote lenvatinib resistance

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Fig. 3 from HSPA6 Confers Lenvatinib Resistance in Hepatocellular Carcinoma by Promoting Phase Separation–Mediated TXNRD1 Stabilization to Suppress Ferroptosis

Yi Zeng, Zhenkun Huang, Jiliang Qiu, Guifang Yuan et autres

HSPA6 suppresses lenvatinib-induced ferroptosis to promote resistance

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Table 8 from HSPA6 Confers Lenvatinib Resistance in Hepatocellular Carcinoma by Promoting Phase Separation–Mediated TXNRD1 Stabilization to Suppress Ferroptosis

Yi Zeng, Zhenkun Huang, Jiliang Qiu, Guifang Yuan et autres

Clinical characteristics of patients who received preoperative lenvatinib treatment

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Table 6 from HSPA6 Confers Lenvatinib Resistance in Hepatocellular Carcinoma by Promoting Phase Separation–Mediated TXNRD1 Stabilization to Suppress Ferroptosis

Yi Zeng, Zhenkun Huang, Jiliang Qiu, Guifang Yuan et autres

List of 568 proteins elevated in tumor tissues from lenvatinib non-responders compared with responders. (Log2 FC > 1, P-value < 0.05)

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Fig. 7 from HSPA6 Confers Lenvatinib Resistance in Hepatocellular Carcinoma by Promoting Phase Separation–Mediated TXNRD1 Stabilization to Suppress Ferroptosis

Yi Zeng, Zhenkun Huang, Jiliang Qiu, Guifang Yuan et autres

Canagliflozin restores ferroptosis sensitivity to lenvatinib in HCC cells

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Table 3 from HSPA6 Confers Lenvatinib Resistance in Hepatocellular Carcinoma by Promoting Phase Separation–Mediated TXNRD1 Stabilization to Suppress Ferroptosis

Yi Zeng, Zhenkun Huang, Jiliang Qiu, Guifang Yuan et autres

The primers used for qPCR assay in present study

0 citations

Accès ouvert 2026 supplementary-materials OpenAlex

Supplementary Table 1 from HSPA6 Confers Lenvatinib Resistance in Hepatocellular Carcinoma by Promoting Phase Separation–Mediated TXNRD1 Stabilization to Suppress Ferroptosis

Yi Zeng, Zhenkun Huang, Jiliang Qiu, Guifang Yuan et autres

Antibodies included in the study

0 citations

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.